Inclusion Criteria:  1. Age: 18-80 years old； 2. Patients with anterior circulation cerebral infarction; 3. first stroke onset or past stroke without obvious neurological deficit (mRS score≤1)； 4. Within 24 hours of onset； 5. 5 ≤NIHSS score ≤ 20； 6. Signed informed consent.  Exclusion Criteria:  1. Patients with hereditary abnormal glucose and lipid metabolism (gangliosidosis, such as Tay-Sachs disease and retinal degeneration); 2. Hemorrhagic stroke; 3. Disturbance of consciousness (NIHSS1a≥1)，or cerebral arteritis, brain tumor, brain trauma, intracranial infectious diseases; 4. Planed endovascular treatment; 5. Uncontrolled hypertension: systolic pressure ≥200 mmHg or diastolic pressure ≥110 mmHg; 6. Bleeding tendency (except for thrombolysis) or severe bleeding within 3 months; 7. Patients with malignant tumor or serious diseases; 8. Along with epilepsy, arthritis and other disease, which have effect on neurological assessment; 9. History of autoimmune diseases, spinal trauma, various demyelinating diseases, including acute inflammatory demyelinating polyneuropathy (Guillain Barre syndrome); 10. Unable or unwilling to cooperate due to mental diseases; 11. Abnormal liver and renal function: ALT, AST > 2 times of the upper limit of normal value, or Cr > 1.5 times of the upper limit of normal value； 12. Hypersensitivity to monosialoganglioside and excipients of test drug; 13. History of drug abuse； 14. Pregnant or lactating women, pregnant plan or unwilling to use effective contraception during the trial period; 15. Participating in other clinical trials within 3 months; 16. Other conditions which are unsuitable for this trial assessed by researcher.